Isoproterenol

Leukemia

University of ArizonaSmall moleculeEarly Phase 1Active

C

34/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 65/ 100

Competitive context

123 Active assets in the Leukemia cohort.

Asset / Sponsor	Phase	Rating
Vincristine Sulfate Inhye Ahn	Phase 3	BB
Cyclophosphamide National Cancer Institute (NCI)	Phase 4	BB
Asparaginase Gruppo Italiano Malattie EMatologiche dell'Adulto	Phase 3	BB
Idarubicin Affiliated Hospital of Nantong University	Phase 3	BB
Thioguanine Anhydrous Incyte Corporation	Phase 3	BB

View all 50 →

Same molecule, other indications

Isoproterenol is also rated in:

lipomaDormant

CCC

Indicative · Phase 1/2

52 / 100

disease related to hematopoietic stem cell transplantActive

C

Indicative · Early Phase 1

39 / 100

lymphomaActive

C

Indicative · Early Phase 1

34 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.